Bisphosphonate-induced osteopetrosis: Novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases

Journal of Bone and Mineral Research

Volumn 23, Issue 10, 2008, Pages 1698-1707

  Whyte, Michael P ^a,b   McAlister, William H ^c   Novack, Deborah V ^b   Clements, Karen L ^a   Schoenecker, Perry L ^b   Wenkert, Deborah ^a  

^a SHRINERS HOSPITAL FOR CHILDREN   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

Alkaline phosphatase; Bone remodeling; Creatine kinase; Endochondral bone; Fracture; Hyperphosphatasemia; Orthodonture; Osteoclast; Osteoclastogenesis; Osteodensitometry; Osteosclerosis; Pamidronate; Skeletogenesis; Spondylolisthesis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

ADOLESCENT; ALBERS SCHOENBERG DISEASE; BONE BIOPSY; BONE DENSITY; BONE GROWTH; BONE PAIN; BONE RADIOGRAPHY; BONE REMODELING; CASE REPORT; CELL SHAPE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CORTICAL BONE; DIAPHYSIS; DRUG EXPOSURE; DRUG INFUSION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR; FRACTURE; FRACTURE HEALING; HIP; HUMAN; HUMAN TISSUE; HYPERPHOSPHATEMIA; ILIAC CREST; LEG FRACTURE; MALE; METACARPAL BONE; OSSIFICATION; OSTEOCLAST; OSTEOPENIA; OSTEOSCLEROSIS; POLARIZATION; RADIUS; SCORING SYSTEM; SKELETON; SPINE; SPONDYLOLISTHESIS; SPONDYLOLYSIS; TRABECULAR BONE;

ADOLESCENT; BONE DISEASES, METABOLIC; BONE REMODELING; CHILD; DIPHOSPHONATES; HUMANS; MALE; OSTEOPETROSIS; OSTEOSCLEROSIS;

EID: 52949116400     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080511     Document Type: Conference Paper

References (50)

1. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S 2003 Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457-463.
2. Adami S, Zamberlan N 1996 Adverse effects of bisphosphonates. A comparative review. Drug Saf 14:158-170.
3. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL 2004 Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62:527-534.
4. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY 2005 Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301.
5. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952.
6. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH 2000 Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85:1846-1850.
7. Whyte MP, Wenkert D, McAlister WH 2003 Bisphosphonates in children with bone diseases (reply letter). N Engl J Med 349:2069-2071.
8. Whyte MP 2002 Osteopetrosis. In: Royce PM, Steinmann B (eds.) Connective Tissue and Its Heritable Disorders: Molecular, Genetic, and Medical Aspects, 2nd ed. Wiley-Liss, New York, NY, USA, pp. 789-807.
9. Williamson A, Hoggart B 2005 Pain: A review of three commonly used pain rating scales. J Clin Nurs 14:798-804.
10. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM 2000 CDC growth charts: United States. Advance Data From Vital and Health Statistics (#314). National Center for Health Statistics, Hyattsville, MD, USA.
11. Tanner JM 1978 Physical growth and development. In: Forfar JO, Arneil GC (eds.) Textbook of Pediatrics. Churchill Livingstone, Edinburgh, UK, pp. 253-303.
12. Roche AF, Mukherjee D, Guo SM, Moore WM 1987 Head circumference reference data: Birth to 18 years. Pediatrics 79:706-712.
13. Kalkwarf HJ, Zemel BS, Gilsanz V, Lappe JM, Horlick M, Oberfield S, Mahboubi S, Fan B, Frederick MM, Winer K, Shepherd JA 2007 The bone mineral density in childhood study: Bone mineral content and density according to age, sex, and race. J Clin Endocrinol Metab 92:2087-2099.
14. Whyte MP, Chines A, Silva DP Jr, Landt Y, Ladenson JH 1996 Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders. J Bone Miner Res 11:1438-1443.
15. Whyte MP, Wenkert D 2006 Lactate dehydrogenase (LDH) isoenzyme elevation in human osteopetrosis. J Bone Miner Res 21:S431.
16. Ott SM 2006 Long-term safety of bisphosphonates. J Clin Endocrinol Metab 90:1897-1899.
17. Armamento-Villareal R, Napoli N, Panwar V, Novack D 2006 Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 355:2048-2050.
18. Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N, Delmas PD 2007 Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: A bone biopsy study. J Bone Miner Res 22:1502-1509.
19. Imai K, Yamamoto S, Anamizu Y, Horiuchi T 2007 Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab 25:333-336.
20. Rauch F, Travers R, Plotkin H, Glorieux FH 2002 The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293-1299.
21. Klein GL, Bachrach LK, Holm IA 2007 Effects of pharmacologic agents on bone in childhood: An editorial overview. Pediatrics 119:S125-S130.
22. Brumsen C, Hamdy NA, Papapoulos SE 1997 Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 76:266-283.
23. Shoemaker LR 1999 Expanding role of bisphosphonate therapy in children. J Pediatr 134:264-267.
24. Hickey J, Lemons D, Waber P, Seikaly MG 2006 Bisphosphonate use in children with bone disease. J Am Acad Orthop Surg 14:638-644.
25. Rauch F, Glorieux FH 2005 Bisphosphonate treatment in osteogenesis imperfecta: Which drug, for whom, for how long? Ann Med 37:295-302.
26. Rauch F, Munns C, Land C, Glorieux FH 2006 Pamidronate in children and adolescents with osteogenesis imperfecta: Effect of treatment discontinuation. J Clin Endocrinol Metab 91:1268-1274.
27. Rauch F, Cornibert S, Cheung M, Glorieux FH 2007 Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 40:821-827.
28. Waterhouse KM, Auron A, Srivastava T, Haney C, Alon US 2007 Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children. Pediatr Nephrol 22:282-287.
29. Ward KA, Adams JE, Freemont TJ, Mughal MZ 2007 Can bisphosphonate treatment be stopped in a growing child with skeletal fragility? Osteoporos Int 18:1137-1140.
30. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC 2005 Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20:977-986.
31. Marini JC 2003 Do bisphosphonates make children's bones better or brittle? N Engl J Med 349:423-426.
32. Papapoulos SE, Cremer SCLM 2007 Prolonged bisphosphonate release after treatment in children. N Engl J Med 356:10.
33. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C 1987 Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16:360-363.
34. Van Persijn van Meerten EL, Kroon HM, Papapoulos SE 1992 Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology 184:249-254.
35. Schenk R, Eggli P, Flesich H, Rosini S 1986 Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38:342-349.
36. Rauch F, Travers R, Munns C, Glorieux FH 2004 Sclerotic metaphyseal lines in a child treated with pamidronate: Histomorphometric analysis. J Bone Miner Res 19:1191-1193.
37. Grissom LE, Kecskemethy HH, Bachrach SJ, McKay C, Harcke HT 2005 Bone densitometry in pediatric patients treated with pamidronate. Pediatr Radiol 35:511-517.
38. Adiyaman P, Ocal G, Berberoglu M, Evliyaoǧlu O, Aycan Z, Cetinkaya E 2004 The clinical and radiological assessment of cyclic intravenous pamidronate administration in children with osteogenesis imperfecta. Turk J Pediatr 46:322-328.
39. Glorieux FH, Rauch F, Shapiro JR 2003 Bisphosphonates in children with bone diseases. (reply letter). N Engl J Med 349:2068-2069.
40. Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML 2003 Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 111:573-578.
41. Bin-Abbas BS, Al-Ashwal AA, Al-Zayed ZS, Sakati NA 2004 Radiological features of bisphosphonate therapy in children with osteogenesis imperfecta. Saudi Med J 11:1772-1773.
42. Srinivasan R 2005 Pamidronate lines. Indian Pediatr 42:959-960.
43. Ward K, Cowell CT, Little DG 2005 Quantification of metaphyseal modeling in children treated with bisphosphonates. Bone 36:999-1002.
44. Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH 2006 Vertebral morphometry in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate treatment. Bone 39:901-906.
45. Land C, Rauch F, Glorieux FH 2006 Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 21:374-379.
46. Vallo A, Rodriguez-Leyva F, Rodriguez Soriano J 2006 Osteogenesis imperfecta: Anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy. Acta Paediatr 95:332-339.
47. Seeman E 2003 Periosteal bone formation - a neglected determinant of bone strength. N Engl J Med 349:320-323.
48. Weinstein RS, Chambers TM, Hogan RS, Webb EE, Wicker CA, Manolagas SC 2007 Giant osteoclast formation after long-term oral aminobisphosphonate therapy for postmenopausal osteoporosis. J Bone Miner Res 22:S1;S17.
49. Martin RP, Deane RH, Collett V 1997 Spondylolysis in children who have osteopetrosis. J Bone Joint Surg Am 79:1685-1689.
50. Åström E, Håkan J, Söderhäll S 2007 Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. Arch Dis Child 92:332-338.